CVA
DGX icon

Ceredex Value Advisors’s Quest Diagnostics DGX Stock Holding History

Ceredex Value Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6M Buy
106,581
+19,469
+22% +$3.82M 0.64% 64
2026
Q1 		$17.1M Buy
+87,112
New +$16.9M 0.54% 84
2020
Q4 		– Sell
-650,600
Closed -$74.5M – 128
2020
Q3 		$74.5M Buy
650,600
+78,100
+14% +$9.23M 1.09% 36
2020
Q2 		$65.2M Buy
+572,500
New +$60.7M 0.97% 41
2020
Q1 		– Sell
-300
Closed -$32K – 140
2019
Q4 		$32K Buy
+300
New +$31.3K ﹤0.01% 153

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Ceredex Value Advisors's DGX Position: Q2 2026 in Review

Ceredex Value Advisors increased its Quest Diagnostics (DGX) stake by 22% in Q2 2026, buying an estimated $3.82M and bringing the position to 106,581 shares worth $22.6M. The position accounts for 0.64% of the portfolio, ranked #64.

Ceredex Value Advisors first reported a position in DGX in Q4 2019 and has held it in 5 quarters since. The position peaked at $74.5M in Q3 2020. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Ceredex Value Advisors held 106,581 shares of Quest Diagnostics worth $22.6M as of Q2 2026.
  • Ceredex Value Advisors bought 19,469 Quest Diagnostics shares in Q2 2026, an estimated $3.82M.
  • Quest Diagnostics made up 0.64% of Ceredex Value Advisors's portfolio in Q2 2026, its #64 holding.
  • Ceredex Value Advisors first reported a position in Quest Diagnostics in Q4 2019 and has held it in 5 quarters since.
  • Ceredex Value Advisors's Quest Diagnostics position peaked at $74.5M in Q3 2020.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Ceredex Value Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.